UGCG and rheumatoid arthritis: These insights suggest that therapies targeting metabolic pathways, such as inhibitors of specific enzymes in glycosphingolipid biosynthesis like glucosylceramide synthase, may modulate macrophage function and reduce inflammation in ACPA− RA.